Press "Enter" to skip to content

Patent delisted for Boehringer Ingelheim drug GLYXAMBI

0
Copyright © DrugPatentWatch. Originally published at Patent delisted for Boehringer Ingelheim drug GLYXAMBI

Annual Drug Patent Expirations for GLYXAMBI
Glyxambi is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from two suppliers. There are eleven patents protecting this drug and one Paragraph IV challenge.

GLYXAMBI drug price trends.

Drug patent litigation for GLYXAMBI.

This drug has four hundred and eighteen patent family members in forty-seven countries.

The generic ingredient in GLYXAMBI is empagliflozin; linagliptin. Two suppliers are listed for this compound. Additional details are available on the empagliflozin; linagliptin profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

Get the Daily Briefing or Try a trial

Copyright © DrugPatentWatch. Originally published at Patent delisted for Boehringer Ingelheim drug GLYXAMBI
    Get the DrugPatentWatch Daily Briefing

    ✓ Patent Expirations and Generic Entry

    ✓ Insightful Articles & Case Studies

    ✓ Patent Litigation & Challenges

    ✓ 505(b)(2) & Biosimilars

    ✓ Industry Trends

    Do NOT follow this link or you will be banned from the site!